New Lungs for Lung Cancer—Perils and Promises

Despite the recent advances in systemic therapy, survival for patients with metastatic non–small cell lung cancer (NSCLC) without actionable genomic alterations in the tumor is limited. A small subset of patients with NSCLC have lung-only metastatic disease and often die of progressive lung failure. In this issue of JAMA, a study by Bharat and colleagues challenges an entrenched assumption that lung transplant has no role in the management of patients with advanced NSCLC with lung-only metastati...